Month: November 2020

With three new trials published this year, there are now 6 clinical trials performed by 5 different groups that support the efficacy of Bumetanide to treat Autism Spectrum Disorders (ASD) symptoms.They are summarized here below:  In addition, 2 eye tracking and functional MRI trials confirm the Bumetanide-dependent amelioration of visual communication and brain imaging alterations that are in keeping with the suggested underlying … Read more

In this trial, the authors report that a 3 months open administration of the NKCC1 chloride importer antagonist Bumetanide (0.5-1mg, twice daily) attenuated Autism Spectrum Disorders (ASD) symptomatology in 11 out of 13 patients (8-21 years old). Bumetanide attenuated Irritable Behavior (ABC-I), Social interactions (SRS) and hyperactivity (ABC- hyperactivity subscale), increased the patients’ estimation of … Read more